RxDoctor Payments Data

Jose Silva, MD

Interventional Cardiology · Slidell, LANPI 1790765394

Payments from drug & device makers

$10,495in general payments, 2019–2025

Across 67 payments — averaging $156.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Angiodynamics, Inc.$9K
  • Baylis Medical Company Inc$352
  • Boston Scientific$308
  • Abbott$175
  • Medtronic$76
  • Veryan Medical Incorporated$69
  • plus $549 from 18 others

What the payments were for

  • Food & beverage$1,75317%
  • Education$3523%
  • Other$8,38980%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,495 in reported general payments places this provider in the 45th percentile of 171 interventional cardiology providers in Louisiana.

See all interventional cardiology providers in Louisiana

Medicare billing

Part B allowed, 2024
$480,523
Medicare patients
571
Services billed
2,521

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban205$147,458
XareltoRivaroxaban98$76,699
EntrestoSacubitril/Valsartan62$41,315
FarxigaDapagliflozin Propanediol48$40,612
BrilintaTicagrelor27$17,046
JardianceEmpagliflozin18$9,798
Ranolazine ErRanolazine153$7,081
Repatha SureclickEvolocumab13$6,796
Repatha SyringeEvolocumab11$5,923
Metoprolol Succinate508$4,255
ClopidogrelClopidogrel Bisulfate557$3,848
Rosuvastatin Calcium373$3,223
Diltiazem 24hr Er (Cd)Diltiazem Hcl141$2,910
Atorvastatin Calcium412$2,425
Ezetimibe178$2,106

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$13$76,69998 claims
AstraZenecaFarxiga, Brilinta$14$57,65875 claims
NovartisEntresto$59$41,31562 claims
Boehringer IngelheimJardiance$17$9,79818 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 171 interventional cardiology providers in Louisiana.

Other interventional cardiology in Slidell

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →